J. Klingemann, Acceptance of Reduced-Risk Drinking as a Therapeutic Goal within the Polish Alcohol Treatment System, Alcohol and Alcoholism, vol.3, issue.4, pp.436-477, 2016.
DOI : 10.1111/j.1360-0443.1986.tb00355.x

H. Rosenberg and A. K. Davis, Differences in the acceptability of non-abstinence goals by type of drug among American substance abuse clinicians, Journal of Substance Abuse Treatment, vol.46, issue.2, pp.214-222, 2014.
DOI : 10.1016/j.jsat.2013.07.005

A. European-medicines, Assessment report: Selincro? international non-proprietory name: nalmefene. EMA/ 78844 Available at, 2012.

A. Braillon, Nalmefene in alcohol misuse: junk evaluation by the European Medicines Agency, BMJ, vol.348, issue.mar10 21, p.2017, 2014.
DOI : 10.1136/bmj.g2017

D. Spence, Bad medicine: nalmefene in alcohol misuse, BMJ, vol.348, issue.feb14 1, p.1531, 2014.
DOI : 10.1136/bmj.g1531

N. Fitzgerald, K. Angus, A. Elders, M. De-andrade, D. Raistrick et al., Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers, Addiction, vol.2, issue.8, pp.1477-87, 2016.
DOI : 10.1371/journal.pmed.0020138

F. Naudet, C. Palpacuer, R. Boussageon, and B. Laviolle, Evaluation in alcohol use disorders ??? insights from the nalmefene experience, BMC Medicine, vol.353, issue.3, p.119, 2016.
DOI : 10.1111/j.1530-0277.2008.00682.x

URL : https://hal.archives-ouvertes.fr/hal-01380423

C. Palpacuer, B. Laviolle, R. Boussageon, J. M. Reymann, E. Bellissant et al., Risks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled Trials, PLOS Medicine, vol.48, issue.12, p.1001924, 2015.
DOI : 10.1371/journal.pmed.1001924.s004

URL : https://hal.archives-ouvertes.fr/hal-01255842

M. Stevenson, A. Pandor, J. W. Stevens, A. Rawdin, P. Rice et al., Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal, PharmacoEconomics, vol.80, issue.8, pp.833-880, 2015.
DOI : 10.1111/j.1360-0443.1985.tb05288.x

J. C. Garbutt, Efficacy and Tolerability of Naltrexone in the Management of Alcohol Dependence, Current Pharmaceutical Design, vol.16, issue.19, pp.2091-2098, 2010.
DOI : 10.2174/138161210791516459

T. Goh, E. Morgan, and M. Y. , Review article: pharmacotherapy for alcohol dependence - the why, the what and the wherefore, Alimentary Pharmacology & Therapeutics, vol.12, issue.Suppl 7, pp.865-82, 2017.
DOI : 10.1111/j.1521-0391.2003.tb00543.x

B. Rolland, F. Paille, C. Gillet, A. Rigaud, R. Moirand et al., Pharmacotherapy for Alcohol Dependence: The 2015 Recommendations of the French Alcohol Society, Issued in Partnership with the European Federation of Addiction Societies, CNS Neuroscience & Therapeutics, vol.103, issue.2, pp.25-37
DOI : 10.1371/journal.pone.0129289

URL : https://hal.archives-ouvertes.fr/hal-01276028

M. Soyka, H. R. Kranzler, V. Hesselbrock, S. Kasper, J. Mutschler et al., Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision, The World Journal of Biological Psychiatry, vol.22, issue.6, pp.86-119, 2017.
DOI : 10.1097/JCP.0000000000000209

R. Burton, C. Henn, D. Lavoie, R. O-'connor, C. Perkins et al., A rapid evidence review of the effectiveness and cost-effectiveness of alcohol control policies: an English perspective, The Lancet, vol.389, issue.10078, pp.1558-80, 2017.
DOI : 10.1016/S0140-6736(16)32420-5

W. Hall and D. Zador, The alcohol withdrawal syndrome, The Lancet, vol.349, issue.9069, pp.1897-900, 1997.
DOI : 10.1016/S0140-6736(97)04572-8

J. D. Amick, H. R. Feltner, C. Bobashev, G. Thomas, K. Wines et al., Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis, JAMA, vol.311, pp.1889-900, 2014.

M. Soyka, M. Friede, and J. Schnitker, Comparing Nalmefene and naltrexone in alcohol dependence: are there any differences? Results from an indirect meta-analysis, Pharmacopsychiatry, vol.49, pp.66-75, 2016.

J. P. Higgins, D. G. Altman, P. C. Gotzsche, P. Juni, D. Moher et al., The Cochrane Collaboration's tool for assessing risk of bias in randomised trials, BMJ, vol.343, issue.oct18 2, p.5928, 2011.
DOI : 10.1136/bmj.d5928

J. P. Higgins and S. Green, Cochrane handbook for systematic reviews of interventions. Cochrane Collaboration. Version 5.1.0. Available at: http://handbook-5-1.cochrane. org/ (accessed 23, 2017.

R. Development and C. Team, R: a Language and Environment for Statistical Computing Vienna: R Foundation for Statistical Computing, 2009.

G. Schwarzer and . Meta, general package for meta-analysis, version 3 Available at: https://cran.r-project, pp.6-6, 2014.

G. Rücker, G. Schwarzer, U. Krahn, J. König, and . Netmeta, Network meta-analysis using frequentist methods. R package version 0.8-0, 2015. (Available at: https://cran.r-project, 2017.

W. Viechtbauer, Conducting meta-analyses in R with the metafor package Available at: http://www.jstatsoft.org/v36, J Stat Softw, vol.36, issue.i03, pp.1-48, 2010.

A. Liberati, D. G. Altman, J. Tetzlaff, C. Mulrow, P. C. Gotzsche et al., The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration, Journal of Clinical Epidemiology, vol.62, issue.10, pp.1-34, 2009.
DOI : 10.1016/j.jclinepi.2009.06.006

B. Hutton, G. Salanti, D. M. Caldwell, A. Chaimani, C. H. Schmid et al., The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations, Annals of Internal Medicine, vol.162, issue.11, pp.777-84, 2015.
DOI : 10.7326/M14-2385

S. Yusuf, R. Peto, J. Lewis, R. Collins, and P. Sleight, Beta blockade during and after myocardial infarction: An overview of the randomized trials, Progress in Cardiovascular Diseases, vol.27, issue.5, pp.335-71, 1985.
DOI : 10.1016/S0033-0620(85)80003-7

G. Rucker, Network meta-analysis, electrical networks and graph theory, Research Synthesis Methods, vol.10, issue.4, pp.312-336, 2012.
DOI : 10.1111/j.1469-1809.1940.tb02257.x

G. Rucker and G. Schwarzer, Ranking treatments in frequentist network meta-analysis works without resampling methods, BMC Medical Research Methodology, vol.17, issue.2, p.58, 2015.
DOI : 10.1016/j.jval.2014.01.004

J. A. Sterne, A. J. Sutton, J. P. Ioannidis, N. Terrin, D. R. Jones et al., Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials, BMJ, vol.343, issue.jul22 1, p.4002, 2011.
DOI : 10.1136/bmj.d4002

G. Salanti, D. Giovane, C. Chaimani, A. Caldwell, D. M. Higgins et al., Evaluating the Quality of Evidence from a Network Meta-Analysis, PLoS ONE, vol.67, issue.6, p.99682, 2014.
DOI : 10.1371/journal.pone.0099682.s003

R. F. Anton, H. Pettinati, A. Zweben, H. R. Kranzler, B. Johnson et al., A Multi-site Dose Ranging Study of Nalmefene in the Treatment of Alcohol Dependence, Journal of Clinical Psychopharmacology, vol.24, issue.4, pp.421-429, 2004.
DOI : 10.1097/01.jcp.0000130555.63254.73

A. Gual, Y. He, L. Torup, W. Van-den-brink, and K. Mann, A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence, European Neuropsychopharmacology, vol.23, issue.11, pp.1432-1474, 2013.
DOI : 10.1016/j.euroneuro.2013.02.006

S. Karhuvaara, K. Simojoki, A. Virta, M. Rosberg, E. Loyttyniemi et al., Targeted Nalmefene With Simple Medical Management in the Treatment of Heavy Drinkers: A Randomized Double-Blind Placebo-Controlled Multicenter Study, Alcoholism: Clinical and Experimental Research, vol.22, issue.7, pp.1179-87, 2007.
DOI : 10.1111/j.1530-0277.2002.tb02486.x

K. Mann, A. Bladstrom, L. Torup, A. Gual, and W. Van-den-brink, Extending the Treatment Options in Alcohol Dependence: A Randomized Controlled Study of As-Needed Nalmefene, Biological Psychiatry, vol.73, issue.8, pp.706-719, 2013.
DOI : 10.1016/j.biopsych.2012.10.020

B. J. Mason, E. C. Ritvo, R. O. Morgan, F. R. Salvato, G. Goldberg et al., A Double-Blind, Placebo-Controlled Pilot Study to Evaluate the Efficacy and Safety of Oral Nalmefene HCI for Alcohol Dependence, Alcoholism: Clinical and Experimental Research, vol.33, issue.5, pp.1162-1169, 1994.
DOI : 10.1001/archpsyc.1976.01770060086012

B. J. Mason, F. R. Salvato, L. D. Williams, E. C. Ritvo, and R. B. Cutler, A Double-blind, Placebo-Controlled Study of Oral Nalmefene for Alcohol Dependence, Archives of General Psychiatry, vol.56, issue.8, pp.719-743, 1999.
DOI : 10.1001/archpsyc.56.8.719

W. Van-den-brink, P. Sorensen, L. Torup, K. Mann, and A. Gual, Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study, Journal of Psychopharmacology, vol.80, issue.8, pp.733-777, 2014.
DOI : 10.1016/j.euroneuro.2011.07.018

J. Ahmadi, M. Babaeebeigi, I. Maany, J. Porter, M. Mohagheghzadeh et al., Naltrexone for alcohol-dependent patients, Irish Journal of Medical Science, vol.139, issue.1, pp.34-37, 2004.
DOI : 10.1007/978-1-4612-0357-5_3

R. F. Anton, H. Myrick, T. M. Wright, P. K. Latham, A. M. Baros et al., Gabapentin Combined With Naltrexone for the Treatment of Alcohol Dependence, American Journal of Psychiatry, vol.168, issue.7, pp.709-726, 2011.
DOI : 10.1176/appi.ajp.2011.10101436

R. Anton, A. Baros, P. Latham, P. Randall, S. Stewart et al., Naltrexone plus aripiprazole compared to naltrexone alone and placebo in the treatment of alcohol dependence? a double blind pilot study, Neuropsychopharmacology, vol.36, pp.234-239, 2011.

D. Davidson, C. Saha, S. Scifres, J. Fyffe, S. O-'connor et al., Naltrexone and brief counseling to reduce heavy drinking in hazardous drinkers, Addictive Behaviors, vol.29, issue.6, pp.1253-1261, 2004.
DOI : 10.1016/j.addbeh.2004.03.027

P. Heinala, H. Alho, K. Kiianmaa, J. Lonnqvist, K. Kuoppasalmi et al., Targeted Use of Naltrexone Without Prior Detoxification in the Treatment of Alcohol Dependence: A Factorial Double-Blind, Placebo-Controlled Trial, Journal of Clinical Psychopharmacology, vol.21, issue.3, pp.287-92, 2001.
DOI : 10.1097/00004714-200106000-00006

T. K. Killeen, K. T. Brady, P. B. Gold, K. N. Simpson, R. A. Faldowski et al., Effectiveness of Naltrexone in a Community Treatment Program, Alcoholism: Clinical & Experimental Research, vol.54, issue.17, pp.1710-1717, 2004.
DOI : 10.1016/0197-2456(88)90048-7

H. R. Kranzler, V. Modesto-lowe, and J. Kirk, Naltrexone vs. Nefazodone for Treatment of Alcohol Dependence A Placebo-Controlled Trial, Neuropsychopharmacology, vol.22, issue.5, pp.493-503, 2000.
DOI : 10.1016/S0893-133X(99)00135-9

H. R. Kranzler, S. Armeli, H. Tennen, O. Blomqvist, C. Oncken et al., Targeted Naltrexone for Early Problem Drinkers, Journal of Clinical Psychopharmacology, vol.23, issue.3, pp.294-304, 2003.
DOI : 10.1097/01.jcp.0000084030.22282.6d

H. R. Kranzler, H. Tennen, S. Armeli, G. Chan, J. Covault et al., Targeted Naltrexone for Problem Drinkers, Journal of Clinical Psychopharmacology, vol.29, issue.4, pp.350-357, 2009.
DOI : 10.1097/JCP.0b013e3181ac5213

URL : http://europepmc.org/articles/pmc3184851?pdf=render

J. Morgenstern, A. N. Kuerbis, A. C. Chen, C. W. Kahler, D. A. Bux et al., A randomized clinical trial of naltrexone and behavioral therapy for problem drinking men who have sex with men., Journal of Consulting and Clinical Psychology, vol.80, issue.5, pp.863-75, 2012.
DOI : 10.1037/a0028615

P. L. Morris, M. Hopwood, G. Whelan, J. Gardiner, and E. Drummond, Naltrexone for alcohol dependence: a randomized controlled trial, Addiction, vol.96, issue.11, pp.1565-73, 2001.
DOI : 10.1046/j.1360-0443.2001.961115654.x

O. Malley, S. S. Corbin, W. R. Leeman, R. F. Demartini, K. S. Fucito et al., Reduction of alcohol drinking in young adults by naltrexone: a double-blind, placebocontrolled , randomized clinical trial of efficacy and safety, J Clin Psychiatry, vol.76, pp.207-220, 2015.

D. W. Oslin, K. G. Lynch, H. M. Pettinati, K. M. Kampman, P. Gariti et al., A Placebo-Controlled Randomized Clinical Trial of Naltrexone in the Context of Different Levels of Psychosocial Intervention, Alcoholism: Clinical and Experimental Research, vol.33, issue.Suppl. 2, pp.1299-308, 2008.
DOI : 10.1001/archpsyc.1997.01830200071010

J. W. Tidey, P. M. Monti, D. J. Rohsenow, C. J. Gwaltney, R. Miranda et al., Moderators of Naltrexone???s Effects on Drinking, Urge, and Alcohol Effects in Non-Treatment-Seeking Heavy Drinkers in the Natural Environment, Alcoholism: Clinical and Experimental Research, vol.44, issue.99, pp.58-66, 2008.
DOI : 10.1001/archpsyc.1992.01820110040006

B. J. Mason, A. M. Goodman, S. Chabac, and P. Lehert, Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: The role of patient motivation, Journal of Psychiatric Research, vol.40, issue.5, pp.383-93, 2006.
DOI : 10.1016/j.jpsychires.2006.02.002

G. Addolorato, F. Caputo, E. Capristo, M. Domenicali, M. Bernardi et al., BACLOFEN EFFICACY IN REDUCING ALCOHOL CRAVING AND INTAKE: A PRELIMINARY DOUBLE-BLIND RANDOMIZED CONTROLLED STUDY, Alcohol and Alcoholism, vol.37, issue.5, pp.504-512, 2002.
DOI : 10.1093/alcalc/37.5.504

G. Addolorato, L. Leggio, A. Ferrulli, S. Cardone, G. Bedogni et al., Dose-Response Effect of Baclofen in Reducing Daily Alcohol Intake in Alcohol Dependence: Secondary Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial, Alcohol and Alcoholism, vol.22, issue.1, pp.312-319, 2011.
DOI : 10.1111/j.1530-0277.2006.00259.x

J. C. Garbutt, A. B. Kampov-polevoy, R. Gallop, L. Kalka-juhl, and B. A. Flannery, Efficacy and Safety of Baclofen for Alcohol Dependence: A Randomized, Double-Blind, Placebo-Controlled Trial, Alcoholism: Clinical and Experimental Research, vol.12, issue.11, pp.1849-57, 2010.
DOI : 10.1001/archpsyc.1965.01720310065008

A. M. Ponizovsky, P. Rosca, E. Aronovich, A. Weizman, and A. Grinshpoon, Baclofen as Add-On to Standard Psychosocial Treatment for Alcohol Dependence: a Randomized, Double-Blind, Placebo-Controlled Trial With 1Year Follow-Up, Journal of Substance Abuse Treatment, vol.52, pp.24-30, 2015.
DOI : 10.1016/j.jsat.2014.11.007

B. A. Johnson, N. Ait-daoud, C. L. Bowden, C. C. Diclemente, J. D. Roache et al., Oral topiramate for treatment of alcohol dependence: a randomised controlled trial, The Lancet, vol.361, issue.9370, pp.1677-85, 2003.
DOI : 10.1016/S0140-6736(03)13370-3

B. A. Johnson, N. Rosenthal, J. A. Capece, F. Wiegand, L. Mao et al., Topiramate for Treating Alcohol Dependence<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>, JAMA, vol.298, issue.14, pp.1641-51, 2007.
DOI : 10.1001/jama.298.14.1641

C. M. Knapp, D. A. Ciraulo, O. Sarid-segal, M. A. Richardson, E. Devine et al., Zonisamide, Topiramate, and Levetiracetam, Journal of Clinical Psychopharmacology, vol.35, issue.1, pp.34-42, 2015.
DOI : 10.1097/JCP.0000000000000246

URL : http://pdfs.journals.lww.com/psychopharmacology/2015/02000/Zonisamide,_Topiramate,_and_Levetiracetam_.6.pdf?token=method|ExpireAbsolute;source|Journals;ttl|1505464132025;payload|mY8D3u1TCCsNvP5E421JYK6N6XICDamxByyYpaNzk7FKjTaa1Yz22MivkHZqjGP4kdS2v0J76WGAnHACH69s21Csk0OpQi3YbjEMdSoz2UhVybFqQxA7lKwSUlA502zQZr96TQRwhVlocEp/sJ586aVbcBFlltKNKo+tbuMfL73hiPqJliudqs17cHeLcLbV/CqjlP3IO0jGHlHQtJWcICDdAyGJMnpi6RlbEJaRheGeh5z5uvqz3FLHgPKVXJzd8ygtSAfJbMLiEzuzQRKgPeapD+wVqp9AKZBxPtOVS/sxrzBAlrfUrywBi3pwvth4;hash|xd8N1YaMzFs3+PQgCR8gsA==

H. R. Kranzler, J. Covault, R. Feinn, S. Armeli, H. Tennen et al., Polymorphism, American Journal of Psychiatry, vol.171, issue.4, pp.445-52, 2014.
DOI : 10.1176/appi.ajp.2013.13081014

G. Addolorato and L. Leggio, Safety and Efficacy of Baclofen in the Treatment of Alcohol-Dependent Patients, Current Pharmaceutical Design, vol.16, issue.19, pp.2113-2120, 2010.
DOI : 10.2174/138161210791516440

E. J. Mills, K. Thorlund, and J. P. Ioannidis, Demystifying trial networks and network meta-analysis, BMJ, vol.346, issue.may14 2, p.2914, 2013.
DOI : 10.1136/bmj.f2914

URL : http://www.bmj.com/content/bmj/346/bmj.f2914.full.pdf

E. Gargon, P. R. Williamson, D. G. Altman, J. M. Blazeby, S. Tunis et al., The COMET Initiative database: progress and activities update (2015), Trials, vol.383, issue.9912, p.54, 2015.
DOI : 10.1016/S0140-6736(13)62227-8

J. P. Jansen and H. Naci, Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers, BMC Medicine, vol.31, issue.1, p.159, 2013.
DOI : 10.1002/sim.5442

N. Institute, C. Health, and . Excellence, Nalmefene for reducing alcohol consumption in people with alcohol dependence: evaluation report Available at: https:// www.nice.org.uk/guidance/ta325?, pp.3629887952016-628192516, 2014.

F. Naudet, Comparing Nalmefene and Naltrexone in Alcohol Dependence: Is there a Spin?, Pharmacopsychiatry, vol.49, issue.06, pp.260-261, 2016.
DOI : 10.1055/s-0042-110493

B. Rolland, F. Paille, B. Fleury, O. Cottencin, A. Benyamina et al., Off-Label Baclofen Prescribing Practices among French Alcohol Specialists: Results of a National Online Survey, PLoS ONE, vol.7, issue.302, p.98062, 2014.
DOI : 10.1371/journal.pone.0098062.t003

A. Braillon, Recommendations of French Alcohol Society and European Federation of Addiction Societies, CNS Neuroscience & Therapeutics, vol.119, issue.6, pp.535-541, 2016.
DOI : 10.1177/1062860616631822

B. Rolland, M. Auffret, and N. Franchitto, Safety reports on the off-label use of baclofen for alcohol-dependence: recommendations to improve causality assessment, Expert Opinion on Drug Safety, vol.37, issue.3, pp.747-51, 2016.
DOI : 10.1111/cns.12489

A. Degrassat-theas, F. Bocquet, M. Sinegre, J. Peigne, and P. Paubel, The ???Temporary Recommendations for Use???: A dual-purpose regulatory framework for off-label drug use in France, Health Policy, vol.119, issue.11, pp.1399-405, 2015.
DOI : 10.1016/j.healthpol.2015.09.003

P. Pommier, G. Debaty, M. Bartoli, D. Viglino, F. Carpentier et al., Severity of Deliberate Acute Baclofen Poisoning: A Nonconcurrent Cohort Study, Basic & Clinical Pharmacology & Toxicology, vol.359, issue.4, pp.360-364, 2014.
DOI : 10.1016/S0140-6736(02)07500-1

A. Braillon and F. Naudet, Baclofen and alcohol use disorders: From miracle to mirage, European Neuropsychopharmacology, vol.27, issue.7, pp.691-693, 2017.
DOI : 10.1016/j.euroneuro.2017.05.003

N. Fritz, S. Glogau, J. Hoffmann, M. Rademacher, C. E. Elger et al., Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy, Epilepsy & Behavior, vol.6, issue.3, pp.373-81, 2005.
DOI : 10.1016/j.yebeh.2005.01.002

J. P. Ioannidis and D. G. Contopoulos-ioannidis, Reporting of safety data from randomised trials, The Lancet, vol.352, issue.9142, pp.1752-1755, 1998.
DOI : 10.1016/S0140-6736(05)79825-1